Feng Lin
Company: Cleveland Clinic
Job title: Researcher
Seminars:
Panel Discussion: Uncovering the Latest Technology in Preclinical Modelling Through the Promise of Humanized Complement Models in Drug Development 9:30 am
Evaluating the utility of humanized complement models for testing complement inhibitors Delving into their advantages for human targeted agents Addressing key challenges such as incomplete humanization, low human protein expression and functional assay development Understanding how humanized complement models can be used to inform complement inhibitor dose predictionRead more
day: Conference Day Two
Repurposing Preclinical Models for Mechanistic Insights & Target Validation to Uncover the Next Generation of Complement Inhibitors 10:00 am
Reframing the primary value of preclinical models to focus on the validation of specific aspects of a drugs mechanism of action Deep-diving into an example to show how humanized complement models can show the effective inhibition of C3 and C3-driven Kidney model Confirming target engagement, particularly for clinically validated targets where the functional outcome is…Read more
day: Conference Day Two
Roundtable: Exploring Current Regulatory Challenges in Complement Inhibitors form IND to Approval 3:30 pm
Join this roundtable to have open and insightful discussions on regulatory experiences with your fellow complement colleagues to gain actionable insights and learnings to bring back to your team. Join the table for the regulatory interaction most relevant to your stage of development.Read more
day: Conference Day Two
Chair’s Closing Remarks 4:30 pm
day: End of Day Two
The Complement Advisory Board Fireside Chat: An Overview of the Complement Therapeutics Landscape 9:00 am
Discussing the dynamic landscape of complement drug development, exploring novel targets and diverse therapeutic modalities and their potential across various diseases, including kidney, CNS, and ophthalmology Addressing critical operational and clinical challenges in complement therapy, delivery, and oral formulations Focussing on the scientific and translational hurdles that remain, covering the importance of developing robust biomarkers,…Read more
day: Conference Day One